New cancer drug enters first human trials for Tough-to-Treat cancers
NCT ID NCT07419841
Summary
This is the first study in humans testing an experimental drug called CTX-10726 for several advanced cancers that have stopped responding to standard treatments. Researchers will give increasing doses to 70 patients to check safety, determine the best dose, and see if the drug shows any early signs of fighting tumors. The study focuses on patients with advanced stomach, liver, uterine, or kidney cancers who have already tried and failed other approved therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
START New York
Lake Success, New York, 11042, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.